Regentatlantic Capital LLC trimmed its stake in Amdocs Limited (NASDAQ:DOX) by 2.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,566 shares of the technology company’s stock after selling 639 shares during the period. Regentatlantic Capital LLC’s holdings in Amdocs were worth $1,960,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Alphasimplex Group LLC bought a new stake in Amdocs in the first quarter valued at $1,691,000. Wedge Capital Management L L P NC grew its position in Amdocs by 17.6% in the first quarter. Wedge Capital Management L L P NC now owns 11,424 shares of the technology company’s stock valued at $618,000 after acquiring an additional 1,707 shares during the period. Machina Capital S.A.S. grew its position in Amdocs by 42.8% in the second quarter. Machina Capital S.A.S. now owns 4,562 shares of the technology company’s stock valued at $283,000 after acquiring an additional 1,368 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its position in Amdocs by 209.1% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,090,517 shares of the technology company’s stock valued at $59,017,000 after acquiring an additional 737,705 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Amdocs in the first quarter valued at $3,623,000. Hedge funds and other institutional investors own 90.80% of the company’s stock.
Amdocs stock traded down $0.83 on Friday, reaching $62.49. The company’s stock had a trading volume of 600,325 shares, compared to its average volume of 525,313. The stock has a market capitalization of $8.93 billion, a P/E ratio of 16.71, a price-to-earnings-growth ratio of 1.88 and a beta of 0.41. The company’s fifty day moving average is $62.88. Amdocs Limited has a twelve month low of $52.60 and a twelve month high of $67.57.
The company also recently declared a quarterly dividend, which was paid on Friday, July 19th. Stockholders of record on Friday, June 28th were paid a dividend of $0.285 per share. This represents a $1.14 annualized dividend and a dividend yield of 1.82%. The ex-dividend date was Thursday, June 27th. Amdocs’s dividend payout ratio (DPR) is presently 30.48%.
A number of analysts have weighed in on the company. Zacks Investment Research cut Amdocs from a “buy” rating to a “hold” rating and set a $67.00 price target on the stock. in a research report on Tuesday, July 16th. ValuEngine raised Amdocs from a “sell” rating to a “hold” rating in a research note on Wednesday, May 15th. TheStreet raised Amdocs from a “c+” rating to a “b-” rating in a research note on Tuesday, June 4th. BidaskClub raised Amdocs from a “sell” rating to a “hold” rating in a research note on Tuesday, June 11th. Finally, JPMorgan Chase & Co. reduced their price objective on Amdocs from $70.00 to $67.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 15th. Four research analysts have rated the stock with a hold rating, The company has a consensus rating of “Hold” and a consensus price target of $67.00.
Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions.
Further Reading: How is the discount rate different from the Federal Funds rate?
Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX).
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.